Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.U.S. sales were 6.84 billion euros, up 11.1%, primarily driven by Immunology, pharma launches, and Lantus, partly offset by vaccines.Pharma increased sales by 57.1% to 1 billion euros, driven by ALTUVIIIO and Ayvakit.The French drug maker reported third-quarter business operating income of 4.45 billion euros, up ...